Previous studies have shown that bone marrow (BM) cells contribute to liver regeneration after tissue injury. The main objective of the present study was to evaluate the feasibility and the safety of the purification and intrahepatic reinfusion of increasing numbers of autologous BM-derived G-CSF-mobilized CD133+ stem cells (SCs) in patients with end-stage liver disease (ESLD). For this purpose, G-CSF at 7.5 µg/Kg/b.i.d. is administered subcutaneously (sc) from day 1 until the completion of peripheral blood stem cells (PBSC) collection. Collection of PBSC begin on day + 5 only if the concentration of CD133+ cells is > 8/µL. CliniMacs device is used for the positive selection of CD133+ SCs (under GMP conditions) from PB of mobilized standard-volume leukapheresis. At least 4 weeks after SC mobilization, collection and cryopreservation, highly purified autologous G-CSF-mobilized CD133+ cells are re-infused through the hepatic artery by transfemoral or transbrachial arteriography. CD133+ cells are administered to patients starting from 5x104/Kg patient’s body weight and increased every 3 patients up to 1x106/kg. G-CSF at 5µg/Kg/day is administered sc for 3 days after the reinfusion of SCs for their expansion and to induce a selective proliferative advantage of reinfused cells in vivo. Biological assays (phenotype of circulating SCs, clonogenic assays, serum cytokines) were done during the mobilization and re-infusion phases together with the phenotypic characterization of the isolated CD133+ SCs. The clinical trial is ongoing. Up to date, 9 patients have been successfully mobilized with G-CSF and highly purified autologous CD133+ SCs have been re-infused in 7 cases. Based on preliminary data, we suggest the feasibility and safety of intrahepatic reinfusion of highly purified CD133+ stem cells in patients with ESLD. Biological studies show that: 1) circulating hematopoietic and endothelial progenitors are increased after G-CSF treatment; 2) highly purified CD133+ cells express hematopoietic and endothelial markers; 3) serum concentration of HGF, SDF-1, VEGF and MMP9 and clonogenic capability of hematopoietic progenitors are increased during the mobilization and re-infusion phases; 4) clonogenic potential of endothelial progenitors shows variable expression.

CD 133+ stem cells for the treatment of end stage liver disease / Brodosi, Lucia; Catani, Lucia; S., Lorenzini; R., Giordano; S., Rizzi; V., Giudice; Sollazzo, Daria; B., Nicolini; E., Montelatici; T., Montemurro; E., Dan; E., Massari; Baccarani, Michele; Bernardi, Mauro; Lemoli, ROBERTO MASSIMO; Andreone, Pietro. - In: DIGESTIVE AND LIVER DISEASE. - ISSN 1590-8658. - 44 Supplement 1:(2012), pp. S7-S7. ((Intervento presentato al convegno A.I.S.F. - Italian Association for the Study of the Liver - Annual Meeting 2012 tenutosi a Roma nel 23 - 24 Febbraio 2012.

CD 133+ stem cells for the treatment of end stage liver disease

BERNARDI, MAURO;LEMOLI, ROBERTO MASSIMO;ANDREONE, PIETRO
2012

Abstract

Previous studies have shown that bone marrow (BM) cells contribute to liver regeneration after tissue injury. The main objective of the present study was to evaluate the feasibility and the safety of the purification and intrahepatic reinfusion of increasing numbers of autologous BM-derived G-CSF-mobilized CD133+ stem cells (SCs) in patients with end-stage liver disease (ESLD). For this purpose, G-CSF at 7.5 µg/Kg/b.i.d. is administered subcutaneously (sc) from day 1 until the completion of peripheral blood stem cells (PBSC) collection. Collection of PBSC begin on day + 5 only if the concentration of CD133+ cells is > 8/µL. CliniMacs device is used for the positive selection of CD133+ SCs (under GMP conditions) from PB of mobilized standard-volume leukapheresis. At least 4 weeks after SC mobilization, collection and cryopreservation, highly purified autologous G-CSF-mobilized CD133+ cells are re-infused through the hepatic artery by transfemoral or transbrachial arteriography. CD133+ cells are administered to patients starting from 5x104/Kg patient’s body weight and increased every 3 patients up to 1x106/kg. G-CSF at 5µg/Kg/day is administered sc for 3 days after the reinfusion of SCs for their expansion and to induce a selective proliferative advantage of reinfused cells in vivo. Biological assays (phenotype of circulating SCs, clonogenic assays, serum cytokines) were done during the mobilization and re-infusion phases together with the phenotypic characterization of the isolated CD133+ SCs. The clinical trial is ongoing. Up to date, 9 patients have been successfully mobilized with G-CSF and highly purified autologous CD133+ SCs have been re-infused in 7 cases. Based on preliminary data, we suggest the feasibility and safety of intrahepatic reinfusion of highly purified CD133+ stem cells in patients with ESLD. Biological studies show that: 1) circulating hematopoietic and endothelial progenitors are increased after G-CSF treatment; 2) highly purified CD133+ cells express hematopoietic and endothelial markers; 3) serum concentration of HGF, SDF-1, VEGF and MMP9 and clonogenic capability of hematopoietic progenitors are increased during the mobilization and re-infusion phases; 4) clonogenic potential of endothelial progenitors shows variable expression.
A.I.S.F. - Italian Association for the Study of the Liver - Annual Meeting 2012
Roma
23 - 24 Febbraio 2012
Brodosi, Lucia; Catani, Lucia; S., Lorenzini; R., Giordano; S., Rizzi; V., Giudice; Sollazzo, Daria; B., Nicolini; E., Montelatici; T., Montemurro; E., Dan; E., Massari; Baccarani, Michele; Bernardi, Mauro; Lemoli, ROBERTO MASSIMO; Andreone, Pietro
CD 133+ stem cells for the treatment of end stage liver disease / Brodosi, Lucia; Catani, Lucia; S., Lorenzini; R., Giordano; S., Rizzi; V., Giudice; Sollazzo, Daria; B., Nicolini; E., Montelatici; T., Montemurro; E., Dan; E., Massari; Baccarani, Michele; Bernardi, Mauro; Lemoli, ROBERTO MASSIMO; Andreone, Pietro. - In: DIGESTIVE AND LIVER DISEASE. - ISSN 1590-8658. - 44 Supplement 1:(2012), pp. S7-S7. ((Intervento presentato al convegno A.I.S.F. - Italian Association for the Study of the Liver - Annual Meeting 2012 tenutosi a Roma nel 23 - 24 Febbraio 2012.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11380/1237082
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact